THE IMPACT OF BIOLOGICAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS ON THE COURSE OF RHEUMATOID ARTHRITIS-ASSOCIATED LUNG DISEASE

被引：0
|
作者：
Avsar, A. Koken [1 ]
Can, G. [1 ]
Birlik, M. [1 ]
Sari, I. [1 ]
Onen, F. [1 ]
机构：
[1] Dokuz Eylul Univ, Dept Rheumatol, Med Sch, Izmir, Turkey
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2020年 / 79卷
关键词：
D O I：
10.1136/annrheumdis-2020-eular.3440
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
FRI0099
引用
收藏
页码：624 / 625
页数：2
相关论文
共 50 条
  • [41] Combination Therapy with Disease Modifying Anti-Rheumatic Drugs in Rheumatoid Arthritis
    Toby Garrood
    David L. Scott
    BioDrugs, 2001, 15 : 543 - 561
  • [42] Pretreatment resistin levels are associated with erosive disease in early rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs and infliximab
    Vuolteenaho, K.
    Tuure, L.
    Nieminen, R.
    Laasonen, L.
    Leirisalo-Repo, M.
    Moilanen, E.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2022, 51 (03) : 180 - 185
  • [43] Anti-nuclear antibody development is associated with poor treatment response to biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis
    Ishikawa, Yuki
    Hashimoto, Motomu
    Ito, Hiromu
    Tanaka, Masao
    Yukawa, Naoichiro
    Fujii, Takao
    Yamamoto, Wataru
    Mimori, Tsuneyo
    Terao, Chikashi
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2019, 49 (02) : 204 - 210
  • [44] The impact of autoantibodies on the efficacy of biological disease-modifying anti-rheumatic drugs in rheumatoid arthritis: meta-analysis of randomized controlled trials
    Takase-Minegishi, Kaoru
    Boehringer, Stefan
    Nam, Jackie L.
    Kaneko, Yuko
    Behrens, Frank
    Saevarsdottir, Saedis
    Detert, Jacqueline
    Leirisalo-Repo, Marjatta
    van der Heijde, Desiree
    Landewe, Robert
    Ramiro, Sofia
    van der Woude, Diane
    RHEUMATOLOGY, 2024, 64 (02) : 548 - 560
  • [45] SUSTAINABILITY OF RESPONSE TO UPADACITINIB AMONG PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS REFRACTORY TO BIOLOGICAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS
    van Vollenhoven, Ronald
    Hall, Stephen
    Wells, Alvin F.
    Meerwein, Sebastian
    Song, Yanna
    Suboticki, Jessica L.
    Fleischmann, Roy
    INTERNAL MEDICINE JOURNAL, 2022, 52 : 29 - 30
  • [46] Sustainability of Response to Upadacitinib Among Patients with Active Rheumatoid Arthritis Refractory to Biological Disease-Modifying Anti-Rheumatic Drugs
    van Vollenhoven, Ronald
    Hall, Stephen
    Wells, Alvin
    Meerwein, Sebastian
    Song, Yanna
    Suboticki, Jessica
    Fleischmann, Roy
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 3534 - 3536
  • [47] Radiographic progression of large joint damage in patients with rheumatoid arthritis treated with biological disease-modifying anti-rheumatic drugs
    Nakajima, Arata
    Aoki, Yasuchika
    Sonobe, Masato
    Takahashi, Hiroshi
    Saito, Masahiko
    Terayama, Keiichiro
    Nakagawa, Koichi
    MODERN RHEUMATOLOGY, 2016, 26 (04) : 517 - 521
  • [48] SUSTAINABILITY OF RESPONSE TO UPADACITINIB AMONG PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS REFRACTORY TO BIOLOGICAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS
    Van Vollenhoven, R.
    Hall, S.
    Wells, A. F.
    Meerwein, S.
    Song, Y.
    Suboticki, J.
    Fleischmann., R. M.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1290 - 1291
  • [49] GUIDELINE ON CONVENTIONAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS
    Galloway, James
    RHEUMATOLOGY, 2016, 55 : 14 - 14
  • [50] Determinants and Impact of Early Initiation of Disease-Modifying Anti-Rheumatic Drug Therapy in Rheumatoid Arthritis
    Keshavamurthy, Chandana
    Kuriakose, Kevin
    Chandra, Deepak
    Kaur, Aneet
    Spencer, Horace
    Khan, Nasim A.
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S1041 - S1041
12345